Physician profile
Aman Kumar Dalal
NPI 1750595575
$21,926.87
in general payments reported to CMS, 2019-2025
25 companies · $762 in 2025
The $762 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,600 · 2020: $4,688 · 2021: $911 · 2022: $1,448 · 2023: $5,246 · 2024: $273 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,410 · Food and Beverage: $1,629 · Travel and Lodging: $225 · Education: $16.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,410.00 |
| Food and Beverage | $1,628.83 |
| Travel and Lodging | $225.00 |
| Education | $16.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16,456.22 | 2019-2025 | Zerbaxa, Recarbrio, Pifeltro |
| Melinta Therapeutics, LLC | $2,216.87 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Gilead Sciences, INC. | $1,022.82 | 2020-2025 | Biktarvy |
| Mayne Pharma Commercial LLC | $461.25 | 2020-2022 | |
| Insmed, INC. | $285.29 | 2021-2025 | Arikayce |
| Abbvie INC. | $274.30 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $253.50 | 2019-2024 | Nuzyra |
| Viiv Healthcare Company | $211.74 | 2021-2025 | Cabenuva, Rukobia |
| La Jolla Pharmaceutical Company | $121.69 | 2021-2025 | Zevtera, Xacduro |
| Astellas Pharma US INC | $88.87 | 2021-2025 | Cresemba |
| Aimmune Therapeutics, INC. | $87.57 | 2025 | Zenpep, Vowst |
| Allergan, INC. | $79.89 | 2019-2020 | |
| Janssen Biotech, INC. | $60.59 | 2022-2023 | Symtuza |
| Shionogi INC | $42.56 | 2021 | |
| Napo Pharmaceuticals INC | $33.65 | 2023-2025 | Mytesi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $32.35 | 2019 | |
| Nabriva Therapeutics, Plc | $32.18 | 2021 | |
| Csl Behring | $31.20 | 2020 | |
| Vyera Pharmaceuticals, LLC | $30.73 | 2022 | |
| Theratechnologies INC. | $19.29 | 2021 | |
| Optinose US, INC. | $18.63 | 2020 | |
| Amgen INC. | $18.36 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.17 | 2023 | |
| Philips North America LLC | $16.75 | 2020 | |
| Echosens North America, INC. | $13.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.